Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-MEL-1 with Anti-PD-1 in Metastatic Melanoma
NCT03743298Phase 1Recruiting
- Sponsor
- AIVITA Biomedical, Inc.
- Start
- Apr 2021
- Primary completion
- May 2024
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AV-MEL-1 in melanoma, sponsored by AIVITA Biomedical, Inc. Primary endpoint: Number of grade 3-5 adverse events with AV-MEL-1 + PD-1 versus PD-1 alone at 3 years. Started Apr 2021; status: recruiting.
02
Drugs
AV-MEL-1
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03743298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743298.